CHUGAI PHARMACEUTICAL CO.,LTD.'s latest stock price, including after-hours PTS trading, was ¥6,750, up ¥4 from the TSE closing price. Earnings information shows that revenue expanded in the interim period of the fiscal year ending December 2026, while profit increased on contributions from key domestic products and overseas revenue. The next earnings announcement is expected around late October 2026.
The current stock price was ¥6,750 in after-hours PTS trading, the quoted trading price as of 23:56, representing a slight change from the previous day's closing price of ¥6,684. After-hours trading is conducted through J-Market, Japan Next Securities' proprietary trading system, and the price was ¥4 above the TSE closing price.
According to a summary of the earnings report, revenue for the interim period of the fiscal year ending December 2026 was ¥663.3 billion, up 14.7% year on year, operating profit was ¥319.6 billion, up 16.9%, and interim profit was ¥231.7 billion, up 19.2%, resulting in higher revenue and profit. Progress against the full-year forecast is considered on track.
Key points to monitor for future performance include risk factors such as the impact of drug price revisions and the penetration of generic drugs, as well as the overseas expansion of key products and growth in royalty income. Analysis based on the earnings report and annual securities report highlights overseas expansion and the impact of domestic drug price trends as medium- to long-term growth factors.
The next earnings announcement is expected around late October 2026, with an outlook based on an AI summary of the earnings report and the annual securities report.